The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

Not yet recruitingOBSERVATIONAL

Enrollment

490

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

December 30, 2025

Conditions

CLL

Interventions

DRUG

Zanubrutinib

patients with treatment naive or R/R CLL who treatment with Zanubrutinib

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Peking University People's Hospital

OTHER

NCT06489184 - The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China | Biotech Hunter | Biotech Hunter